Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3) - Pipeline Review, H1 2016 - Global Markets Direct - Market Research

Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3) - Pipeline Review, H1 2016

Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3) - Pipeline Review, H1 2016 - Global Markets Direct - Market Research
Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3) - Pipeline Review, H1 2016
Published Jun 30, 2016
61 pages — Published Jun 30, 2016
Price US$ 3,500.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

Global Markets Directs, Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3) - Pipeline Review, H1 2016, provides in depth analysis on Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3) targeted pipeline therapeutics.

The report provides comprehensive information on the Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3)
- The report reviews Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3) targeted therapeutics and enlists all their major and minor projects
- The report assesses Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targete

  
Source:
Document ID
GMDHC0254TDB
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents24
  List of Tables51
  List of Figures51
Introduction61
  Global Markets Direct Report Coverage61
Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3) Overview71
Therapeutics Development83
  Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3) Products under Development by Stage of Development81
  Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3) Products under Development by Therapy Area91
  Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3) Products under Development by Indication101
Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3) Pipeline Products Glance113
  Late Stage Products111
  Early Stage Products121
  Unknown Stage Products131
Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3) Products under Development by Companies142
Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3) Products under Development by Universities/Institutes162
Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3) Therapeutics Assessment186
  Assessment by Monotherapy/Combination Products181
  Assessment by Mechanism of Action191
  Assessment by Route of Administration202
  Assessment by Molecule Type222
Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3) Companies Involved in Therapeutics Development245
  Merck &Co., Inc.241
  SciFluor Life Sciences, LLC251
  Tissue Therapies Limited261
  TWi Pharmaceuticals, Inc.271
  Vascular Pharmaceuticals, Inc.281
Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3) Drug Profiles2918
  A-11 Drug Profile291
  AC-301 Drug Profile301
  C-16Y Drug Profile311
  cilengitide Drug Profile322
  MK-0429 Drug Profile341
  OCU-200 Drug Profile351
  Peptides to Antagonize Alpha-V Beta-3 Integrin Receptor for Melanoma Drug Profile361
  Proagio Drug Profile371
  RSF-201 Drug Profile381
  SF-0166 Drug Profile391
  SOM-0777 Drug Profile401
  tetraiodothyroacetic acid Drug Profile411
  VF-001 Drug Profile421
  VF-002 Drug Profile431
  VF-003 Drug Profile441
  VF-004 Drug Profile451
  VPI-2690B Drug Profile461
Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3) Dormant Projects474
Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3) Discontinued Products511
Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3) Featured News &Press Releases528
  May 31, 2016: New Class of Protein Could Treat Cancer and Other Diseases, Georgia State Researchers Find521
  May 25, 2016: Iceni Pharmaceuticals launches as new company focusing on repurposing therapies in the field of oncology531
  Mar 09, 2016: SciFluor Life Sciences Awarded Second U.S. Patent for Integrin av 3 (SF0166) Inhibitors Designed for the Topical Treatment of Retinal Disease531
  Feb 11, 2016: Ocugen Announces Patent Allowance For Ocu-200541
  Dec 17, 2015: Tissue Therapies Provides FDA Regulatory Progress Update541
  Feb 25, 2013: Merck Serono Announces Phase III Trial Of Cilengitide Did Not Meet Primary Endpoint In Patients With Newly Diagnosed Glioblastoma552
  Jun 09, 2011: Merck Serono Completes Patient Enrollment For Cilengitide s Pivotal Phase III Trial CENTRIC571
  Jun 05, 2010: EMD Serono Announces Long-Term Follow-up Data From Cilengitide Study In Glioblastoma Patients571
  May 31, 2009: Study Shows Cilengitide Increased Overall Survival In Patients With Glioblastoma581
  Mar 16, 2009: Merck Serono Expands Cilengitide Development Program591
  Jan 01, 2004:591
Appendix602
  Methodology601
  Coverage601
  Secondary Research601
  Primary Research601
  Expert Panel Validation601
  Contact Us601
  Disclaimer611

Table Of Contents

Global Markets Direct - Market Research—Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information.

About the Author


Cite this Report

  
MLA:
Global Markets Direct - Market Research. "Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3) - Pipeline Review, H1 2016" Jun 30, 2016. Alacra Store. Nov 16, 2026. <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Integrin-Beta-3-Platelet-Membrane-Glycoprotein-IIIa-or-CD61-or-ITGB3-Pipeline-Review-H1-2016-2088-16125>
  
APA:
Global Markets Direct - Market Research. (2016). Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3) - Pipeline Review, H1 2016 Jun 30, 2016. New York, NY: Alacra Store. Retrieved Nov 16, 2026 from <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Integrin-Beta-3-Platelet-Membrane-Glycoprotein-IIIa-or-CD61-or-ITGB3-Pipeline-Review-H1-2016-2088-16125>
  
US$ 3,500.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.